Cycle Pharmaceuticals has signed an agreement with Catalent to develop innovative formulations targeting rare disease patients. This agreement covers four products in rare metabolic and neurological disorders and each product will utilize Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies.
The Zydis Ultra platform is the company’s next generation ODT technology and allows for increased drug load and better taste masking to be incorporated into its proven Zydis ODT dosage form.
“Cycle’s core area of expertise is to improve rare disease medicines in order to make life easier for patients of all ages,” Antonio Benedetti, CEO of Cycle said. “These drug products will benefit patients with a broad range of unmet needs. Zydis technology has consistently proven its effectiveness in overcoming challenges faced by patients, such as swallowing difficulties and large pill burdens. Working in partnership with Catalent to apply the Zydis technology to Cycle’s product pipeline will be life-changing for both patients and their caregivers.”
“Catalent has proven experience and expertise in drug formulation and working with partners to bring new therapies to market quickly,” Jonathan Arnold, President of Catalent’s Oral Drug Delivery business said. “The Zydis technology platform has been shown to be very versatile and effective in developing easy-to-administer dose forms for innovators, and having evaluated Cycle’s molecules at our Swindon, U.K., facility, we believe them to be excellent candidates for further development.”